Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2021 | $26.00 → $27.00 | Buy | Citigroup |
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step
PALO ALTO, Calif., May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock option to purchase 120,000 shares of Eiger's common stock. The stock option was approved by the Compensation Committee of Eiger's Board of Directors and granted under the Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan, as amended, with a grant date of April 30, 2023, as an
PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones. "This is a pivotal year for Eiger as we plan for topline data from the landmark D-LIVR study by year end. D-LIVR is the largest trial conducted in HDV and if positive will support re
8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
10-K/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024David Apelian, MD, PhD, MBA, appointed CEOLive conference call and webcast at 8:30 am ET todayPALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development effor
Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ETPALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET. Conference Call Details The live and replayed webcast of the call will be available through the company's website at
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV. The live and replayed webcast of the call will be available through the company's websi
Announces "Stalking Horse" Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas. The company also announced a "stalking horse" agreement for the sale of Zokinvy® (lonafarnib) to Sentynl Therapeutics, Inc., a biopharmaceutical company focused on rare diseases. Under the terms of the "stalking horse" agreement, subject to court
Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeriaEiger to receive $500,000 approval milestone payment from AnGesZokinvy approved in the U.S. (2020), 30 European countries (2022), and now Japan (2024)PALO ALTO, Calif., Jan. 18, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchin
PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time, on January 5, 2024. The Company's common stock will begin trading on a post-split basis at the market open on January 8, 2024. The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requireme
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
Citigroup reiterated coverage of Eiger BioPharmaceuticals with a rating of Buy and set a new price target of $27.00 from $26.00 previously
SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increased by 6.76% to $3.47. The company's market cap stands at $103.3 million. GRI Bio (NASDAQ:GRI) stock increased by 6.65% to $0.54. NuCana (NASDAQ:NCNA) shares rose 5.92% to $0.25. The market value of their outstanding shares is at $13.4 million. Stoke Therapeutics (NASDAQ:STOK) shares increased by 5.42% to $12.83. The company's market cap stands at $594.0 million. Candel Therapeutics (NASDAQ:CADL) stock moved upwards by 4.99% to $6.72. The market value of their outstanding shares is at $197
Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares climbed 130.1% to $2.9790. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies. Allurion Technologies Inc. (NASDAQ:ALUR) gained 70% to $2.8801 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock w
Gainers Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 61.38% to $2.1. The market value of their outstanding shares is at $5.0 million. Eiger BioPharmaceuticals (NASDAQ:EIGR) shares moved upwards by 38.18% to $2.28. The company's market cap stands at $3.3 million. Macrogenics (NASDAQ:MGNX) stock rose 32.55% to $18.12. The company's market cap stands at $1.1 billion. Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 29.55% to $3.77. The company's market cap stands at $146.7 million. Curis (NASDAQ